GSA Capital Partners LLP lifted its position in Johnson & Johnson (NYSE:JNJ) by 149.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,268 shares of the company’s stock after purchasing an additional 16,951 shares during the quarter. Johnson & Johnson accounts for 0.3% of GSA Capital Partners LLP’s portfolio, making the stock its 25th largest position. GSA Capital Partners LLP’s holdings in Johnson & Johnson were worth $3,675,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. grew its position in Johnson & Johnson by 1.5% in the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after acquiring an additional 3,023,110 shares during the period. BlackRock Inc. grew its holdings in shares of Johnson & Johnson by 2.6% during the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after purchasing an additional 4,332,612 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Johnson & Johnson by 0.4% during the third quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock worth $4,757,593,000 after purchasing an additional 130,437 shares during the last quarter. FMR LLC grew its holdings in shares of Johnson & Johnson by 5.9% during the second quarter. FMR LLC now owns 27,237,648 shares of the company’s stock worth $3,603,268,000 after purchasing an additional 1,509,745 shares during the last quarter. Finally, Capital World Investors grew its holdings in shares of Johnson & Johnson by 4.1% during the second quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock worth $3,507,009,000 after purchasing an additional 1,050,000 shares during the last quarter. Institutional investors and hedge funds own 67.35% of the company’s stock.
In related news, VP Paulus Stoffels sold 155,342 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the transaction, the vice president now owns 357,906 shares in the company, valued at $46,477,673.16. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.19% of the stock is owned by company insiders.
Johnson & Johnson (NYSE:JNJ) opened at $133.06 on Friday. The stock has a market capitalization of $355,001.63, a PE ratio of 18.13, a P/E/G ratio of 2.10 and a beta of 0.77. Johnson & Johnson has a 1-year low of $120.95 and a 1-year high of $148.32. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.51.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.02. The business had revenue of $20.20 billion for the quarter, compared to analysts’ expectations of $20.08 billion. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The firm’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same quarter last year, the business earned $1.58 earnings per share. equities analysts forecast that Johnson & Johnson will post 8.11 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th were issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.53%. The ex-dividend date was Monday, February 26th. Johnson & Johnson’s dividend payout ratio is 861.54%.
JNJ has been the topic of several research analyst reports. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 target price on the stock in a report on Thursday, January 11th. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Jefferies Group set a $165.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a report on Monday, February 26th. Stifel Nicolaus increased their target price on Johnson & Johnson from $142.00 to $145.00 and gave the stock a “hold” rating in a report on Wednesday, January 24th. Finally, Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Four investment analysts have rated the stock with a sell rating, nine have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $146.26.
TRADEMARK VIOLATION WARNING: This report was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/03/16/gsa-capital-partners-llp-purchases-16951-shares-of-johnson-johnson-jnj.html.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.